Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.53 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134525 | 1.00 | SLC6A1 (0.53) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL132090 | 1.00 | SLC6A1 (0.53) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5215224 | 0.98 | SLC6A1 (0.52) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL22444028 | 0.98 | SLC6A1 (0.52) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL205293 | 0.98 | SLC6A1 (0.52) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL14525966 | 0.95 | ALDH1A1 (0.50) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL29295425 | 0.93 | ALDH1A1 (0.53) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Chloroacetic Acid SCHEMBL27501180 | 0.91 | SLC6A1 (0.49) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Cadaverine Tartrate SCHEMBL4889376 | 0.89 | SLC6A1 (0.47) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Cadaverine Tartrate SCHEMBL6970212 | 0.89 | SLC6A1 (0.47) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184650-A | 6- (1H-pyrrolo [2,3-b ] pyridin-3-yl) quinazoline-4-amine derivative, and preparation method and application thereof | 中国人民解放军北部战区总医院 | 2024-06-14 | — | — | CN | claimed |
| CN-116947879-A | BBI608 derivative, preparation method thereof and application thereof in preparing medicines for treating STAT3 mediated diseases | 沈阳药科大学 | 2023-10-27 | — | — | CN | claimed |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12527886-B2 | Radiopharmaceuticals and composition for thrombus imaging | THE ASAN FOUNDATION (KR) | 2026-01-20 | — | — | US | disclosed |
| EP-4678626-A1 | LONG-CHAIN ALKENYLOXY-SUBSTITUTED BENZOYL DERIVATIVE AND OLIGONUCLEOTIDE SYNTHESIS METHOD USING SAME | Spera Pharma, Inc. (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-12459915-B2 | Biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2025-11-04 | — | — | US | disclosed |
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4626892-A1 | ADENOSINE A2A AND A2B RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4071147-B1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEMICAL LTD (KR) | 2025-03-26 | — | — | EP | disclosed |
| US-20250019371-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-01-16 | — | — | US | disclosed |
| US-5608069-A | TREATMENT OF NERVOUS SYSTEM DISORDERS WITH GAMMA-AMINOBUTYRIC ACID | NOVO NORDISK A/S (DK) | 1997-03-04 | — | — | US | disclosed |
| US-5604242-A | ALKOXY- AND CARBOXY-SUBSTITUTED PIPERIDINES FOR SUPPRESSING UPTAKE OF GAMMA-AMINOBUTYRIC ACID, ANALGESICS, ANXIOLYTIC OR ANTIEPILEPTIC AGENTS | NOVO NORDISK A/S (DK) | 1997-02-18 | — | — | US | disclosed |
| WO-1996031497-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
| EP-0705248-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1996-04-10 | — | — | EP | disclosed |
| EP-0705247-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1996-04-10 | — | — | EP | disclosed |
| EP-0705246-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000483-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1995-01-05 | — | — | WO | disclosed |
| WO-1995000486-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1995-01-05 | — | — | WO | disclosed |
| WO-1995000485-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | POLRMT, TFAM, POLM | SLC6A1 4781/4885SLC6A11 4812/4885TSHR 2586/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | SLC6A1 511/4885SLC6A11 587/4885TSHR 2229/4885 |
| US-12527886-B2 | Radiopharmaceuticals and composition for thrombus imaging | F11, CD274, SERPINC1 | SLC6A1 580/4885SLC6A11 125/4885TSHR 32/4885 |
| US-20250019371-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | SLC6A1 4759/4885SLC6A11 4740/4885TSHR 4372/4885 |
| US-12459915-B2 | Biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, LCAT | SLC6A1 3604/4885SLC6A11 3751/4885TSHR 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.